Benitec Biopharma, Inc. (BNTC)
8.28
+0.13
(+1.60%)
USD |
NASDAQ |
Nov 18, 16:00
8.28
0.00 (0.00%)
After-Hours: 20:00
Benitec Biopharma Enterprise Value : 108.51M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 108.51M |
| November 16, 2026 | 122.11M |
| November 13, 2026 | 139.56M |
| November 12, 2026 | 141.30M |
| November 11, 2026 | 154.56M |
| November 10, 2026 | 147.93M |
| November 09, 2026 | 168.52M |
| November 06, 2026 | 157.00M |
| November 05, 2026 | 125.60M |
| November 04, 2026 | 147.93M |
| November 03, 2026 | 117.23M |
| November 02, 2026 | 120.37M |
| October 30, 2026 | 129.09M |
| October 29, 2026 | 132.23M |
| October 28, 2026 | 131.19M |
| October 27, 2026 | 127.00M |
| October 26, 2026 | 123.86M |
| October 23, 2026 | 125.95M |
| October 22, 2026 | 131.88M |
| October 21, 2026 | 120.72M |
| October 20, 2026 | 139.56M |
| October 19, 2026 | 115.83M |
| October 16, 2026 | 107.11M |
| October 15, 2026 | 119.32M |
| October 14, 2026 | 113.39M |
| Date | Value |
|---|---|
| October 13, 2026 | 125.25M |
| October 12, 2026 | 140.61M |
| October 09, 2026 | 133.63M |
| October 08, 2026 | 129.44M |
| October 07, 2026 | 137.81M |
| October 06, 2026 | 138.16M |
| October 05, 2026 | 146.19M |
| October 02, 2026 | 137.47M |
| October 01, 2026 | 158.40M |
| September 30, 2026 | 173.05M |
| September 29, 2026 | 156.24M |
| September 28, 2026 | 165.53M |
| September 25, 2026 | 150.73M |
| September 24, 2026 | 152.45M |
| September 23, 2026 | 158.99M |
| September 22, 2026 | 197.54M |
| September 21, 2026 | 195.13M |
| September 18, 2026 | 199.95M |
| September 17, 2026 | 211.65M |
| September 16, 2026 | 200.64M |
| September 15, 2026 | 200.98M |
| September 14, 2026 | 236.43M |
| September 11, 2026 | 240.22M |
| September 10, 2026 | 241.25M |
| September 09, 2026 | 249.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 20.36B |
| Ionis Pharmaceuticals, Inc. | 4.776B |
| ACADIA Pharmaceuticals, Inc. | 2.261B |
| Anika Therapeutics, Inc. | 153.30M |
| Savara, Inc. | 821.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.92M |
| Total Expenses (Quarterly) | 12.92M |
| EPS Diluted (Quarterly) | -0.2612 |
| Earnings Yield | -13.68% |
| Normalized Earnings Yield | -13.68 |